Payne D N, Wilson N M, James A, Hablas H, Agrafioti C, Bush A
Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK.
Thorax. 2001 May;56(5):345-50. doi: 10.1136/thorax.56.5.345.
Children with difficult asthma experience frequent symptoms despite treatment with high dose inhaled steroids. Persistent symptoms may result from persistent airway inflammation which can be monitored by measuring exhaled nitric oxide (NO). This study aimed to assess the role of airway inflammation, using NO as a surrogate, in children with difficult asthma and to investigate the response to oral prednisolone.
NO was measured in 23 children (mean age 11.7 years) with difficult asthma, before and after 2 weeks of treatment with oral prednisolone. The clinical response was assessed by spirometric tests, peak flow, bronchodilator use, and symptoms. Adherence to treatment was assessed by measuring serum prednisolone and cortisol concentrations. NO was measured in 55 healthy children to establish a normal range.
NO concentrations were higher in asthmatic patients than in controls (geometric mean 11.2 v 5.3 ppb, p<0.01). Using grouped data, the concentration of NO fell following prednisolone (11.2 v 7.5 ppb, p<0.01) accompanied by an improvement in morning peak flow (p<0.05). The baseline NO concentration was raised (>12.5 ppb) in nine asthmatic patients and remained high after prednisolone in five. Thirteen had normal levels of NO (<12.5 ppb) before and after prednisolone. Thirteen asthmatic patients remained symptomatic following prednisolone; NO levels were raised on both occasions in five of these and were normal in seven.
As a group, the asthmatic subjects demonstrated evidence of airway inflammation which responded to prednisolone. At least two subgroups of patients were identified: one with persistently raised NO levels despite treatment with oral prednisolone indicating ongoing steroid insensitive inflammation, and another with normal levels of NO. Both subgroups included patients with persistent symptoms, which suggests that different patterns of difficult asthma in children exist.
尽管使用高剂量吸入性类固醇进行治疗,但难治性哮喘患儿仍频繁出现症状。持续的症状可能源于持续的气道炎症,可通过测量呼出一氧化氮(NO)来监测。本研究旨在评估以NO作为替代指标的气道炎症在难治性哮喘患儿中的作用,并研究口服泼尼松龙的反应。
对23名难治性哮喘患儿(平均年龄11.7岁)在口服泼尼松龙治疗2周前后测量NO。通过肺功能测试、呼气峰流速、支气管扩张剂使用情况和症状来评估临床反应。通过测量血清泼尼松龙和皮质醇浓度来评估治疗依从性。对55名健康儿童测量NO以建立正常范围。
哮喘患者的NO浓度高于对照组(几何平均数分别为11.2 ppb和5.3 ppb,p<0.01)。使用分组数据,泼尼松龙治疗后NO浓度下降(11.2 ppb对7.5 ppb,p<0.01),同时晨峰流速有所改善(p<0.05)。9名哮喘患者的基线NO浓度升高(>12.5 ppb),其中5名在泼尼松龙治疗后仍保持高水平。13名患者在泼尼松龙治疗前后的NO水平正常(<12.5 ppb)。13名哮喘患者在泼尼松龙治疗后仍有症状;其中5名患者的NO水平在两种情况下均升高,7名患者的NO水平正常。
作为一个群体,哮喘受试者表现出气道炎症的证据,且对泼尼松龙有反应。至少确定了两个患者亚组:一组患者尽管口服泼尼松龙治疗,但NO水平持续升高,表明存在持续的类固醇不敏感炎症;另一组患者的NO水平正常。两个亚组均包括有持续症状的患者,这表明儿童难治性哮喘存在不同模式。